These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 9780653)

  • 1. [Clinical study of carcinoma in situ of the urinary bladder].
    Harada Y; Seguchi T; Nonomura N; Kojima Y; Miki T; Okuyama A
    Nihon Hinyokika Gakkai Zasshi; 1998 Aug; 89(8):693-7. PubMed ID: 9780653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis.
    Takashi M; Katsuno S; Yuba H; Ohshima S; Wakai K; Ohno Y
    Int Urol Nephrol; 1998; 30(6):713-22. PubMed ID: 10195866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder.
    Takashi M; Shimoji T; Murase T; Sakata T; Sobajima T; Suzuki Y
    Int Urol Nephrol; 1997; 29(5):557-63. PubMed ID: 9413763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Squamous cell carcinoma of the urinary bladder after intravesical bacillus Calmette-Guerin therapy for carcinoma in situ: a case report].
    Uemura M; Nishimura K; Nakagawa M; Kanno N; Miyoshi S; Kawano K; Inoue H
    Hinyokika Kiyo; 2004 Nov; 50(11):809-11. PubMed ID: 15628544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
    Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases.
    Sallami S; Khouni H; Ben Atta M; Abou El Makarim S; Zouari MB; Ben Rhouma S
    Tunis Med; 2016 Dec; 94(12):844. PubMed ID: 28994883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study of primary carcinoma in situ of the bladder].
    Mori Y; Shima H; Ihara H; Yabumoto H; Taguchi K; Koike H; Nojima M; Yamamoto H; Ikoma F
    Hinyokika Kiyo; 1996 Jan; 42(1):17-21. PubMed ID: 8686577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.
    Tan WS; Panchal A; Buckley L; Devall AJ; Loubière LS; Pope AM; Feneley MR; Cresswell J; Issa R; Mostafid H; Madaan S; Bhatt R; McGrath J; Sangar V; Griffiths TRL; Page T; Hodgson D; Datta SN; Billingham LJ; Kelly JD
    Eur Urol; 2019 Jan; 75(1):63-71. PubMed ID: 30274699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.
    De Jager R; Guinan P; Lamm D; Khanna O; Brosman S; De Kernion J; Williams R; Richardson C; Muenz L; Reitsma D
    Urology; 1991 Dec; 38(6):507-13. PubMed ID: 1836081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    Narayan VM; Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown G; Canter D; Luchey A; Lotan Y; Inman BA; Williams MB; Cookson MS; Chang SS; Sankin AI; O'Donnell MA; Sawutz D; Philipson R; Parker NR; Yla-Herttuala S; Rehm D; Jakobsen JS; Juul K; Dinney CPN
    J Urol; 2024 Jul; 212(1):74-86. PubMed ID: 38704840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
    Okuno H; Shirahase T; Kihara Y; Arai Y
    Hinyokika Kiyo; 1989 Sep; 35(9):1503-7. PubMed ID: 2816616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma].
    Nguyen-Huu Y; Delorme G; Lillaz J; Bedgedjian I; Le Ray-Ferrières I; Chabannes E; Bernardini S; Guichard G; Bittard H; Kleinclauss F
    Prog Urol; 2012 May; 22(5):284-90. PubMed ID: 22515925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical Bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder.
    Ovesen H; Poulsen AL; Steven K
    Br J Urol; 1993 Nov; 72(5 Pt 2):744-8. PubMed ID: 8281407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
    Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
    Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total cystectomy after intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer: experience in Japan.
    Takashi M; Kondo A; Nakano Y; Takagi Y; Sakata T; Miyake K
    Int Urol Nephrol; 1994; 26(1):33-42. PubMed ID: 8026921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.